Search for new potential anticonvulsants with anxiolytic and antidepressant properties among derivatives of 4,4-diphenylpyrrolidin-2-one

被引:6
作者
Malawska, Katarzyna [1 ]
Rak, Aleksandra [1 ]
Gryzlo, Beata [1 ]
Salat, Kinga [2 ]
Michalowska, Malgorzata [2 ,3 ]
Zmudzka, Elzbieta [2 ]
Lodarski, Krzysztof [2 ]
Malawska, Barbara [1 ]
Kulig, Katarzyna [1 ]
机构
[1] Jagiellonian Univ, Coll Med, Fac Pharm, Dept Physicochem Drug Anal, Medyczna 9 St, PL-30688 Krakow, Poland
[2] Jagiellonian Univ, Coll Med, Fac Pharm, Dept Pharmacodynam, Medyczna 9 St, PL-30688 Krakow, Poland
[3] Med Univ Bialystok, Dept Pharmacodynam, Mickiewicza 2C St, PL-15222 Bialystok, Poland
关键词
Substituted pyrrolidin-2-one derivatives; MES test; scPTZ test; Anxiolytic-like activity; Antidepressant-like activity; MAXIMAL ELECTROSHOCK; ANTIEPILEPTIC DRUGS; SEIZURE MODELS; MICE; EPILEPSY; RECEPTORS; MECHANISM; AFFINITY; RATS;
D O I
10.1016/j.pharep.2016.09.020
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The aim of this study was to synthesize a series of new N-Mannich bases derived from 4,4-diphenylpyrrolidin-2-one having differently substituted 4-phenylpiperazines as potential anticonvulsant agents with additional (beneficial) pharmacological properties. Methods: The target compounds 8-12 were prepared in one step from the 4-substituted phenylpiperazines, paraformaldehyde, and synthesized 4,4-diphenylpyrrolodin-2-one (7) by a Mannich-type reaction. The obtained compounds were assessed and tested for their anticonvulsant activity in two screening mouse models of seizures, i.e., the maximal electroshock (MES) test and in the subcutaneous pentylenetetrazole (scPTZ) test. The effect of these compounds on animals' motor coordination was measured in the rotarod test. A selected 4,4-diphenyl-1-((4-phenylpiperazin-1-yl)methyl)pyrrolidin-2-one (8) was evaluated in vivo for its anxiolytic- and antidepressant-like properties. Its impact on animals' locomotor activity was also evaluated. Results: Compound 8 showed protection (25%) in the MES and in the scPTZ tests at the dose of 100 mg/kg and was not neurotoxic. In the four-plate test, compound 8 at the dose of 30 mg/kg showed a statistically significant (p < 0.05) anxiolytic-like activity. In the forced swim test, it reduced the immobility time by 24.3% (significant at p < 0.05), which indicates its potential antidepressant-like properties. In the locomotor activity test, compound 8 significantly reduced animals' locomotor activity by 79.9%. Conclusion: The results obtained make a new derivative of 4,4-diphenyl-1((4-phenylpiperazin-1-yl) methyl)pyrrolidin-2-one (8) a promising lead structure for further development. (C) 2016 Published by Elsevier Sp. z o.o. on behalf of Institute of Pharmacology, Polish Academy of Sciences.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 20 条
[1]   Anxiolytic-like effect of milnacipran in the four-plate test in mice:: Mechanism of action [J].
Bourin, M ;
Masse, F ;
Dailly, E ;
Hascoët, M .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2005, 81 (03) :645-656
[2]   Mechanisms of disease - Epilepsy [J].
Chang, BS ;
Lowenstein, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1257-1266
[3]   A NOTE ON A SIMPLE APPARATUS FOR DETECTING NEUROLOGICAL DEFICIT IN RATS AND MICE [J].
DUNHAM, NW ;
MIYA, TS .
JOURNAL OF THE AMERICAN PHARMACEUTICAL ASSOCIATION, 1957, 46 (03) :208-209
[4]  
Landmark CJ, 2008, CNS DRUGS, V22, P27
[5]   Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs [J].
Loescher, Wolfgang .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2011, 20 (05) :359-368
[6]   Arylpiperazine derivatives acting at 5-HT1A receptors [J].
López-Rodríguez, ML ;
Ayala, D ;
Benhamù, B ;
Morcillo, MJ ;
Viso, A .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (04) :443-469
[7]   THE ROLE OF TECHNICAL, BIOLOGICAL AND PHARMACOLOGICAL FACTORS IN THE LABORATORY EVALUATION OF ANTICONVULSANT DRUGS .2. MAXIMAL ELECTROSHOCK SEIZURE MODELS [J].
LOSCHER, W ;
FASSBENDER, CP ;
NOLTING, B .
EPILEPSY RESEARCH, 1991, 8 (02) :79-94
[8]  
Luszczki JJ, 2009, PHARMACOL REP, V61, P252
[9]  
Malawska B, 2005, CURR TOP MED CHEM, V5, P69, DOI 10.2174/1568026053386944
[10]  
McNamara J., 2011, PHARM BASIS THERAPEU